Adelphi Real World
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor (NCT07166315) | Adelphi Real World | 2025-07-07 |
Track Adelphi Real World automatically
Every clearance here is in the API, with alerts when new ones post.